Revenue: CHF134.6m (down 18% from 1H 2024).
Net loss: CHF8.90m (down by 165% from CHF13.7m profit in 1H 2024).
CHF0.40 loss per share (down from CHF0.61 profit in 1H 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue missed analyst estimates by 29%. Earnings per share (EPS) was also behind analyst expectations.
Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland.
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for SKAN Group that you should be aware of.